Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Jason Cormier

Neurological Surgery Lafayette, LA Medical Doctor

NPI 1982812723 CMS profile 44770

155 Hospital Dr, Suite 100, Lafayette, LA 70503

Open in the dashboard

General payments

$178,075

176 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Jason Cormier of Lafayette, LA is reported in the CMS Open Payments database as having received $178,075 across 176 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 93rd percentile of Neurological Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $14,044 14
2024 General $2,314 3
2023 General $16,322 19
2022 General $51,988 31
2021 General $43,581 16
2020 General $27,108 34
2019 General $22,719 59

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jason Cormier
  • Neurological Surgery median
  • Middle half of Neurological Surgery
  • National median

In program year 2025, general payments to Jason Cormier were reported at $14,044. Among 5,467 Neurological Surgery profiles paid that year, the median was $596 and the middle half received between $159 and $3,102.

Show as a table
Year Jason Cormier Neurological Surgery median Middle half National median
2019 $22,719 $582 $138–$3,006 $163
2020 $27,108 $294 $76–$2,174 $114
2021 $43,581 $387 $105–$2,432 $132
2022 $51,988 $542 $139–$2,989 $149
2023 $16,322 $534 $145–$2,697 $160
2024 $2,314 $574 $155–$3,046 $164
2025 $14,044 $596 $159–$3,102 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. The Institute of Musculoskeletal Science and Education $79,088 23 payments
  2. MiRus, LLC $78,687 30 payments
  3. Sanara MedTech Inc. $5,414 2 payments
  4. Orthofix Medical, Inc. $3,117 17 payments
  5. Alphatec Spine, Inc $2,868 12 payments
  6. Cerapedics, Inc. $1,655 2 payments
  7. Stryker Corporation $1,386 18 payments
  8. Augmedics Inc. $1,098 4 payments
  9. Camber Spine Technologies $1,088 12 payments
  10. Aesculap Implant Systems, LLC $705 7 payments
  11. Other $2,970 49 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Royalty or License $145,477 27 payments
  2. Travel and Lodging $14,086 33 payments
  3. Food and Beverage $8,241 110 payments
  4. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $5,570 3 payments
  5. Consulting Fee $3,200 2 payments
  6. Honoraria $1,500 1 payment
Products named General payments · program years 2019–2025
  1. EUROPA Pedicle Screw System $75,687 29 payments
  2. CYGNUS Anterior Cervical Plate $73,497 27 payments
  3. IO Expandable Lumbar Interbody $59,863 9 payments
  4. RIGEL 3DR Cervical Interbody $36,326 6 payments
  5. MiRus 3DR Lumbar Interbody System $36,326 6 payments
  6. Enza 2.0 $28,167 8 payments
  7. Spira $24,482 8 payments
  8. Enza $12,078 2 payments
  9. Xvision $5,490 20 payments
  10. CellerateRx $5,414 2 payments
  11. Other $18,255 107 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 1 drug

Part D claims

11

Median for Neurosurgery: 83

Drug cost

$168

Median for Neurosurgery: $872

Branded share of claims

100%

Median for Neurosurgery: 16.5%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 11 $168

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 2,779 Part D prescribers listed as Neurosurgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 71 billing codes

Paid by Medicare

$189,977

Medicare's payments for the services billed

Medicare patients

207

Average age 72

Services billed

596

105 women, 102 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Diabetes 41%
Ischemic heart disease 41%
Depression 35%
Chronic kidney disease 26%
Atrial fibrillation 23%
Heart failure 19%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

176 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record